Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oncorine + Tislelizumab + Chemo in Advanced NSCLC
NCT06136910Phase 2Recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- May 2023
- Primary completion
- May 2024
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of Oncorine in non-small cell lung cancer (NSCLC), sponsored by Fujian Medical University Cancer Hospital. Started May 2023; status: recruiting.
02
Drugs
Oncorine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06136910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06136910.